Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BMP1 | P13497 | 7/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1596987 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1596978 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4583761 | 0.87 | BMP1 (0.65) | ALDH1A1HPGDBMP1MMP12 | |
| SCHEMBL1596230 | 0.87 | BMP1 (0.65) | ALDH1A1HPGDBMP1MMP12 | |
| SCHEMBL1596233 | 0.87 | BMP1 (0.65) | ALDH1A1HPGDBMP1MMP12 | |
| SCHEMBL6024195 | 0.83 | BMP1 (0.59) | NPC1RAB9ABMP1MMP12POLB | |
| SCHEMBL1596333 | 0.80 | BMP1 (0.49) | BMP1 | |
| SCHEMBL1596337 | 0.80 | BMP1 (0.49) | BMP1 | |
| SCHEMBL1596338 | 0.80 | BMP1 (0.49) | BMP1 | |
| SCHEMBL1596956 | 0.79 | TSHR (0.43) | HPGDBMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | claimed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | claimed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1509218-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
| EP-1509218-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101442-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161249-A1 | Use of Novel Antibacterial Compounds | MRPL21, NRDC, SPOUT1 | ALDH1A1 4213/4885HPGD 1855/4885NPC1 724/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | ALDH1A1 4302/4885HPGD 2537/4885NPC1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.